Abstract |
Astilbin, a major bioactive compound extracted from Rhizoma smilacis glabrae (RSG), has been reported to possess immunosuppressive properties. Our study first evaluated the effect of astilbin on experimental autoimmune myasthenia gravis (EAMG) in Lewis rats. The results showed that astilbin could attenuate the severity of EAMG by decreasing antigen-specific autoantibodies with up-regulation of regulatory T cells and down-regulation of Th17 cells. In addition to, astilbin also reduced the efficiency of the antigen presenting cells on which the expression of MHC class II decreased. These results suggest that astilbin might be a candidate drug for immunoregulation of EAMG, and provide us new treatment ideas for human myasthenia gravis (MG).
|
Authors | Qing-Fang Meng, Zheng Zhang, Yan-Jun Wang, Wei Chen, Fei-Fei Li, Long-Tao Yue, Chang-Jun Zhang, Heng Li, Min Zhang, Cong-Cong Wang, Peng Zhang, Hui Chen, Rui-Sheng Duan, Shan-Mei Sun, Yan-Bin Li |
Journal | Journal of neuroimmunology
(J Neuroimmunol)
Vol. 298
Pg. 138-45
(09 15 2016)
ISSN: 1872-8421 [Electronic] Netherlands |
PMID | 27609287
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2016. Published by Elsevier B.V. |
Chemical References |
- Anti-Inflammatory Agents
- Antigens, CD
- Cytokines
- Flavonols
- HLA-DR alpha-Chains
- astilbin
- Sincalide
|
Topics |
- Analysis of Variance
- Animals
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Antigens, CD
(metabolism)
- Body Weight
(drug effects)
- Cell Proliferation
(drug effects)
- Cytokines
(metabolism)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Female
- Flavonols
(pharmacology, therapeutic use)
- Flow Cytometry
- HLA-DR alpha-Chains
(metabolism)
- Myasthenia Gravis, Autoimmune, Experimental
(drug therapy, immunology)
- Rats
- Rats, Inbred Lew
- Sincalide
(metabolism)
- T-Lymphocytes, Regulatory
(drug effects)
- Th17 Cells
(drug effects)
|